Radiopharm Theranostics (RADX) Stock Price, News & Analysis

Company Overview

Radiopharm Theranostics Limited is a clinical-stage biotechnology company focused on developing radiopharmaceuticals for the diagnosis and treatment of cancer. Its approach combines targeted molecules with radioactive isotopes to help identify tumors through medical imaging and deliver radiation directly to cancer cells.

The company’s pipeline includes diagnostic and therapeutic programs based on peptides, small molecules and antibodies. These programs are designed to address cancers with significant unmet medical needs, including solid tumors and other difficult-to-treat malignancies. Radiopharm’s development activities include preclinical research and clinical studies evaluating the safety, imaging performance and therapeutic potential of its candidates.

Radiopharm Theranostics is headquartered in Australia and conducts development activities through collaborations and clinical programs in international markets, including the United States. The company is led by Chief Executive Officer and Managing Director Paul Hopper. Its shares trade on the Australian Securities Exchange under the symbol RAD and on the Nasdaq under the symbol RADX.

Key Stats

• Today's Range: $1.06 to $1.24
• 50-Day Range: $1.11 to $3.11
• 52-Week Range: $1.00 to $16.25
• Volume: 65,763 shs
• Average Volume: 62,240 shs
• Market Capitalization: $17.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Hold

Radiopharm Theranostics Stock Analysis - MarketRank™

Radiopharm Theranostics scored higher than 69% of companies evaluated by MarketBeat, and ranked 219th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Radiopharm Theranostics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Radiopharm Theranostics has a consensus price target of $11.00, representing about 873.5% upside from its current price of $1.13.

Amount of Analyst Coverage

Radiopharm Theranostics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Radiopharm Theranostics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.22% of the float of Radiopharm Theranostics has been sold short.

Short Interest Ratio / Days to Cover

Radiopharm Theranostics has a short interest ratio ("days to cover") of 0.62, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Radiopharm Theranostics has recently decreased by 18.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Radiopharm Theranostics does not currently pay a dividend.

Dividend Growth

Radiopharm Theranostics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.03

News Sentiment

Radiopharm Theranostics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Radiopharm Theranostics this week, compared to 2 articles on an average week.

MarketBeat Follows

3 people have added Radiopharm Theranostics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Radiopharm Theranostics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Radiopharm Theranostics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/31/2026
• Today: 10/10/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RADX
• CIK: 1949257
• Web: www.radiopharmtheranostics.com
• Phone: 61-3-9824-5254
• Fax: N/A
• Employees: 14
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Radiopharm Theranostics: $11.00
• High Price Target: $16.00
• Low Price Target: $6.00
• Potential Upside/Downside: +873.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.16
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: $1.88 million
• Price / Sales: 9.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.28 per share
• Price / Book: 0.88

Miscellaneous

• Outstanding Shares: 15,700,000
• Free Float: N/A
• Market Cap: $17.74 million
• Optionable: N/A
• Beta: 1.78